Activating Transcription Factor 6 (ATF6) Peptide

Details for Product No. ABIN499350
Request Want additional data for this product?

The Independent Validation Initiative strives to provide you with high quality data. Find out more

Protein Name
Origin
Human
(3), (2)
Source
Synthetic
Application
Control Peptide (CP)
Pubmed 4 references available
Quantity 50 µg
Shipping to United States (Change)
Availability Discontinued
Request Want additional data for this product?

The Independent Validation Initiative strives to provide you with high quality data. Find out more

Catalog No. ABIN499350
170.50 $
Plus shipping costs $45.00
Add to Basket

Order hotline:

  • +1 404 474 4654
  • +1 888 205 9894 (TF)
Specificity 16 amino acids near the carboxy terminus of human ATF6.
Purification purified
Alternative Name ATF6 alpha
Background Alternate names: ATF-6, Activating transcription factor 6 alpha, Cyclic AMP-dependent transcription factor ATF-6 alpha, cAMP-dependent transcription factor ATF-6 alpha
Gene ID 22926
NCBI Accession NP_031374
UniProt P18850
Application Notes ATF6 peptide is used for blocking the activity of ATF6 antibody. It usually blocks theantibody activity completely in Western blot by incubating the peptide with equal volumeof antibody for 30 min at 37°C. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
Restrictions For Research Use only
Format Liquid
Concentration 0.2 mg/mL
Buffer PBS pH7.2 (10 mM NaH2PO4, 10 mM Na2HPO4, 130 mM NaCl) containing 0.1 % bovine serum albumin and 0.02 % sodium azide
Preservative Sodium azide
Precaution of Use This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Handling Advice Avoid repeated freezing and thawing.
Storage -20 °C
Storage Comment Store at -20 °C.
Expiry Date 12 months
Background publications Dillon, Sprecher, Hammond et al.: "Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice." in: Nature immunology, Vol. 5, Issue 7, pp. 752-60, 2004 (PubMed).

Dreuw, Radtke, Pflanz et al.: "Characterization of the signaling capacities of the novel gp130-like cytokine receptor." in: The Journal of biological chemistry, Vol. 279, Issue 34, pp. 36112-20, 2004 (PubMed).

Diveu, Lak-Hal, Froger et al.: "Predominant expression of the long isoform of GP130-like (GPL) receptor is required for interleukin-31 signaling." in: European cytokine network, Vol. 15, Issue 4, pp. 291-302, 2005 (PubMed).

Bilsborough, Leung, Maurer et al.: "IL-31 is associated with cutaneous lymphocyte antigen-positive skin homing T cells in patients with atopic dermatitis." in: The Journal of allergy and clinical immunology, Vol. 117, Issue 2, pp. 418-25, 2006 (PubMed).

Validation Images
back to top